Background We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18)
human papillomavirus (HPV) vaccine to the current screening programme in the UK …

Human Papillomavirus (HPV) vaccines will likely have an impact as a preventive strategy for
cervical cancer. Screening for precancerous lesions cannot be discontinued because …

Background. The ongoing development of a vaccine against human papillomavirus (HPV)
raises important questions about the impact of various vaccination strategies. Methods. Two …

Background Previously, we demonstrated similar human papillomavirus (HPV) 16/18
vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination …

Randomized clinical trials are currently examining the efficacy of a nonavalent human
papillomavirus (HPV) vaccine, including HPV‐types 6/11/16/18/31/33/45/52/58. Evidence on …

Background Three-dose regimens for human papillomavirus (HPV) vaccines are expensive
and difficult to complete, especially in settings where the need for cervical cancer prevention …

Abstract The American Cancer Society (ACS) has developed guidelines for the use of the
prophylactic human papillomavirus (HPV) vaccine for the prevention of cervical …

Background The primary goal of human papillomavirus (HPV) vaccination is to reduce
morbidity and mortality from HPV-associated disease, especially cervical cancer. We …

Abstract Background The United States (US) Food & Drug Administration (FDA) recently
approved a human papillomavirus (HPV) vaccine with the purpose of reducing the risk of …

Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are
currently in human clinical trials. The main long-term goal of the vaccine is to reduce the …